Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development
January 09 2017 - 8:01AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, today announced that Mark E. Dudley,
Ph.D. has joined the company as Senior Vice President of
Global Bio-Process and Development.
Dr. Dudley has been a pioneer in the field of immunotherapy
manufacturing, and has developed and implemented innovative early
process design with accompanying analytics for multiple therapies.
Prior to joining Adaptimmune, Dr. Dudley was the Director of New
Cell Products for Cell and Gene Therapy at Novartis in Cambridge,
MA where he served on the technical R&D leadership team, and
was responsible for establishing scalable, GMP‑compliant
production strategies, and facilitating globalization of CAR-T
products and platforms. Prior to joining Novartis, Dr. Dudley
served as Director of the Cell Production Facility at the National
Cancer Institute (NCI) in Bethesda, MD where he also led scientific
and technical innovation enabling key milestones in immuno-oncology
success. Dr. Dudley’s work has resulted in more than 100
peer-reviewed publications, and he is co-author on numerous seminal
papers including early tumor-infiltrating lymphocytes studies
demonstrating that adoptive T-cell transfer has tumor eradicating
potential.
“We are delighted to have Dr. Dudley join our Adaptimmune team,”
said Gwendolyn Binder-Scholl, Ph.D., Adaptimmune’s Chief Technology
Officer. “Mark is one of the most highly experienced T-cell
manufacturing scientists in the world, and he also has hands-on
experience with the unique commercial challenges for this emerging
therapeutic modality. I look forward to supporting Mark in
the planning and execution of his vision for continuous innovation
in and delivery of our SPEAR® T-cell therapy manufacture, in
clinical development and future commercialization.”
Before joining the NIH and subsequently Novartis, Dr. Dudley
earned his Ph.D. in Biological Sciences at Stanford University, and
had post-doctoral fellowships at The University of Pennsylvania in
Philadelphia, PA, and at the Jackson Laboratory in Bar Harbor,
ME.
Dr. Dudley said: “I am very excited to join Adaptimmune. The
Company has already made great progress in establishing a
commercial-ready process for SPEAR T-cell manufacturing, and I look
forward to working with the team to further enhance efficiencies
and drive continuous improvement to meet the needs of our
patients.”
About AdaptimmuneAdaptimmune is a clinical
stage biopharmaceutical company focused on novel cancer
immunotherapy products based on its SPEAR (Specific Peptide
Enhanced Affinity Receptor) T-cell platform. Established in 2008,
the Company aims to utilize the body’s own machinery - the T-cell -
to target and destroy cancer cells by using engineered, increased
affinity TCRs as a means of strengthening natural patient T-cell
responses. Adaptimmune’s lead program is a SPEAR T-cell therapy
targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell
therapy has demonstrated signs of efficacy and tolerability in
Phase 1/2 trials in solid tumors and in hematologic cancer types,
including synovial sarcoma and multiple myeloma. Adaptimmune has a
strategic collaboration and licensing agreement with
GlaxoSmithKline for the development and commercialization of the
NY-ESO TCR program. In addition, Adaptimmune has multiple
proprietary programs. These include SPEAR T-cell therapies
targeting the MAGE-A10, AFP, and MAGE-A4 cancer antigens, which all
have open INDs. The Company has identified over 25 intracellular
target peptides preferentially expressed in cancer cells and is
currently progressing 12 through unpartnered research programs.
Adaptimmune has over 250 employees and is located in Oxfordshire,
U.K. and Philadelphia, USA. For more information:
http://www.adaptimmune.com
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
on November 10, 2016, and our other SEC filings. The
forward-looking statements contained in this press release speak
only as of the date the statements were made and we do not
undertake any obligation to update such forward-looking statements
to reflect subsequent events or circumstances.
Adaptimmune Contacts
Investor Relations
Will Roberts
T: (215) 825-9306
E: will.roberts@adaptimmune.com
Juli P. Miller, Ph.D.
T: (215) 825-9310
E: juli.miller@adaptimmune.com
Media Relations
Margaret Henry
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024